Amalgamated Bank Sells 75 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Amalgamated Bank lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,279 shares of the biopharmaceutical company’s stock after selling 75 shares during the period. Amalgamated Bank’s holdings in Alnylam Pharmaceuticals were worth $2,277,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company’s stock valued at $1,792,542,000 after purchasing an additional 50,366 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Alnylam Pharmaceuticals by 5.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after buying an additional 201,784 shares during the last quarter. Capital International Investors increased its holdings in shares of Alnylam Pharmaceuticals by 1.8% in the first quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock worth $545,674,000 after buying an additional 64,560 shares during the period. Capital Research Global Investors increased its holdings in shares of Alnylam Pharmaceuticals by 7.3% in the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock worth $470,018,000 after buying an additional 214,908 shares during the period. Finally, Bellevue Group AG lifted its stake in shares of Alnylam Pharmaceuticals by 3.7% in the 1st quarter. Bellevue Group AG now owns 918,284 shares of the biopharmaceutical company’s stock valued at $137,238,000 after acquiring an additional 32,966 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the sale, the chief executive officer now owns 73,441 shares in the company, valued at $20,563,480. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

ALNY has been the topic of several recent research reports. The Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price target for the stock from $198.00 to $370.00 in a research report on Friday, August 16th. TD Cowen raised their target price on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Chardan Capital reiterated a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. JPMorgan Chase & Co. increased their price target on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a research report on Monday, August 26th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Six analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $294.50.

Alnylam Pharmaceuticals Trading Up 0.9 %

NASDAQ ALNY opened at $279.82 on Tuesday. The firm has a market capitalization of $36.09 billion, a PE ratio of -106.80 and a beta of 0.39. The stock’s 50 day moving average is $274.52 and its 200 day moving average is $232.41. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. The company’s quarterly revenue was down 33.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.15 EPS. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.